Teva Pharma Industries Ltd ADR (TEVA) Peer Comparison
$36.07
$-0.38
(-1.03%)
As on 31-Aug-2026 15:44EDT
Market cap
$42,895 Mln
Revenue (TTM)
$17,314 Mln
P/E Ratio
62.4
P/B Ratio
5.6
Div. Yield
0 %
Edit
| Teva Pharma Industries Ltd ADR (TEVA) | Takeda Pharmaceutical Company Limited (TAK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
42,895 | 57,898 | 1,109,683 | 644,335 | 462,684 |
Revenue ($ Mln) |
17,314 | 4,660,556 | 79,666 | 97,929 | 64,386 |
Net Profit ($ Mln) |
706.00 | 182,139.19 | 26,709.50 | 21,037.00 | 6,314.00 |
Net Margin (%) |
4.08 | 3.91 | 33.53 | 21.48 | 9.81 |
RoE (%) |
9.00 | 2.39 | 88.42 | 25.27 | -- |
Price to Earnings |
62.39 | -- | 42.93 | 31.75 | 75.24 |
Price-To-Book |
5.63 | 1.23 | 33.69 | 7.75 | 50.46 |
Income Statement ($ Mln)
| Teva Pharma Industries Ltd ADR (TEVA) | Takeda Pharmaceutical Company Limited (TAK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
17,314.00 | 4,660,556.24 | 79,665.80 | 97,929.00 | 64,386.00 |
|
Cost of Revenue
|
8,232.00 | 1,910,441.47 | 12,737.00 | 28,936.00 | 18,365.00 |
|
Gross Profit
|
8,938.00 | 3,001,334.00 | 54,615.00 | 68,558.00 | 42,956.00 |
|
Operating Expenses
|
7,099.00 | 2,238,097.90 | 31,939.40 | 42,737.00 | 27,142.00 |
|
Operating Profit (EBIT)
|
1,983.00 | 512,016.87 | 34,989.40 | 26,256.00 | 18,879.00 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
720.00 | 273,729.51 | 33,594.40 | 25,196.00 | 8,699.00 |
|
Provision for Tax
|
12.00 | 91,299.48 | 6,884.90 | 4,159.00 | 2,383.00 |
|
Profit after Tax (Net Income)
|
706.00 | 182,139.19 | 26,709.50 | 21,037.00 | 6,314.00 |
|
Minority Interest
|
-1.00 | -288.00 | 0.00 | 0.00 | -6.00 |
|
Consolidated Profit
|
0.00 | 91,838.00 | 12,218.50 | 10,268.00 | 0.00 |
Liabilities ($ Mln)
| Teva Pharma Industries Ltd ADR (TEVA) | Takeda Pharmaceutical Company Limited (TAK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
7,757.00 | 7,557,887.00 | 33,879.00 | 84,971.00 | -5,935.00 |
|
Minority Interest
|
-1.00 | -288.00 | 0.00 | 0.00 | -6.00 |
|
Non-Current Liabilities
|
16,450.00 | 5,339,848.00 | 60,663.00 | 61,195.00 | 99,361.00 |
|
Current Liabilities
|
15,646.00 | 2,764,547.00 | 47,741.00 | 54,895.00 | 41,642.00 |
|
Total Liabilities
|
40,747.37 | 14,248,344.00 | 112,476.00 | 199,210.00 | 133,960.00 |
Assets ($ Mln)
| Teva Pharma Industries Ltd ADR (TEVA) | Takeda Pharmaceutical Company Limited (TAK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
26,097.00 | 12,513,001.00 | 77,611.00 | 141,286.00 | 101,446.00 |
|
Current Assets
|
13,760.00 | 3,150,269.00 | 64,672.00 | 59,774.00 | 33,669.00 |
|
Total Assets
|
40,747.37 | 14,248,344.00 | 112,476.00 | 199,210.00 | 133,960.00 |
|
Total Debt*
|
16,874.00 | 4,939,968.00 | 54,908.00 | 49,036.00 | 70,822.00 |
|
Net Current Assets
|
-1,886.00 | 385,722.00 | 16,931.00 | 4,879.00 | -7,973.00 |
Cashflow ($ Mln)
| Teva Pharma Industries Ltd ADR (TEVA) | Takeda Pharmaceutical Company Limited (TAK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
1,649.00 | 1,057,182.00 | 16,813.00 | 24,530.00 | 19,030.00 |
|
Cash Flow from Investing Activities
|
737.00 | -367,060.00 | -10,972.00 | -23,588.00 | -6,643.00 |
|
Cash from Financing Activities
|
-2,151.00 | -751,425.00 | -2,213.00 | -5,539.00 | -12,724.00 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Teva Pharma Industries Ltd ADR (TEVA) | Takeda Pharmaceutical Company Limited (TAK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
5.79 | 0.92 | 35.32 | 22.56 | 6.17 |
|
ROE (%)
|
9.00 | 2.39 | 88.42 | 25.27 | 6,214.71 |
|
ROA (%)
|
1.31 | 1.05 | 16.19 | 8.36 | 3.57 |
|
EBIT Margin (%)
|
9.27 | 12.68 | 31.17 | 26.53 | 20.68 |
|
Net Margin (%)
|
4.08 | 3.91 | 33.53 | 21.48 | 9.81 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Teva Pharma Industries Ltd ADR (TEVA) | Takeda Pharmaceutical Company Limited (TAK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
4.13 | 4.02 | 49.58 | 8.06 | 10.39 |
|
EBIT Growth (%)
|
-17.94 | 33.36 | 39.73 | -7.83 | 125.97 |
|
Net Profit Growth (%)
|
546.84 | 33.07 | 93.55 | -7.17 | 67.79 |
|
EPS Growth (%)
|
505.13 | 32.75 | 94.62 | -7.72 | 67.77 |
|
Book Value Growth (%)
|
11.70 | 8.95 | 86.67 | 7.35 | -4,203.16 |
Valuation Ratios
| Teva Pharma Industries Ltd ADR (TEVA) | Takeda Pharmaceutical Company Limited (TAK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
25.96 | 0.44 | 46.76 | 18.83 | 95.92 |
|
Price / Book Value
|
4.63 | 0.01 | 36.37 | 6.19 | -125.57 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
16.06 | 3.43 | 35.81 | 12.97 | 26.61 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Teva Pharma Industries Ltd ADR (TEVA) | Takeda Pharmaceutical Company Limited (TAK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
1.56 | 0.58 | 1.41 | 0.44 | -10.53 |
|
Short term debt to equity ratio
|
0.58 | 0.07 | 0.21 | 0.14 | -1.41 |
|
Current Ratio
|
0.88 | 1.14 | 1.35 | 1.09 | 0.81 |
|
Quick Ratio
|
0.67 | 0.62 | 1.00 | 0.81 | 0.69 |
|
Interest Coverage
|
1.80 | 1.86 | 35.29 | 25.90 | 3.98 |
Operating Efficiency Ratios
| Teva Pharma Industries Ltd ADR (TEVA) | Takeda Pharmaceutical Company Limited (TAK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
20.17 | 20.52 | 29.47 | 19.45 | 21.47 |
|
Asset Turnover
|
0.32 | 0.27 | 0.48 | 0.39 | 0.36 |
|
Receivable days
|
71.62 | 56.72 | 93.67 | 70.00 | 70.20 |
|
Inventory Days
|
135.78 | 280.51 | 368.80 | 189.75 | 91.61 |
|
Payable days
|
103.91 | 72.62 | 148.80 | 158.88 | 65.58 |
|
Cash Conversion Cycle
|
103.49 | 264.60 | 313.66 | 100.87 | 96.23 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
